Table 1. Select trials in Ph-like ALL... | American Society of Hematology

Table 1.

Select trials in Ph-like ALL

Target	Agent	Clinical trial #	Phase	Age (years)	Disease status	Results
JAK	Ruxolitinib	NCT02723994	2	1-21	Newly diagnosed	Tasian et al⁵⁵
JAK	Ruxolitinib	NCT03571321	1	18-39	Newly diagnosed	N/A
JAK ABL	Ruxolitinib Dasatinib	NCT02420717	1/2	10+	R/R	Jain et al⁵⁶

Target	Agent	Clinical trial #	Phase	Age (years)	Disease status	Results
JAK	Ruxolitinib	NCT02723994	2	1-21	Newly diagnosed	Tasian et al⁵⁵
JAK	Ruxolitinib	NCT03571321	1	18-39	Newly diagnosed	N/A
JAK ABL	Ruxolitinib Dasatinib	NCT02420717	1/2	10+	R/R	Jain et al⁵⁶